GRN and ovarian cancer: GP88 expression has also been reported in relation to different cancer treatment resistance mechanisms such as letrozole and tamoxifen resistance in breast cancer cells [27,34], temozolomide resistance of glioblastoma [35], dexamethasone resistance in multiple melanoma [37], and chemoresistance to cisplatin in ovarian cancer cell lines [38].